- #3,116
mfb
Mentor
- 37,274
- 14,119
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial
Conclusion of a phase 1 vaccine trial. 108 participants split into three dose groups, most showed some mild adverse reaction (typically pain at the injection site), no one showed a serious adverse reaction, all participants formed antibodies. Higher doses lead to more antibodies, but also lead to stronger adverse reactions.
Conclusion of a phase 1 vaccine trial. 108 participants split into three dose groups, most showed some mild adverse reaction (typically pain at the injection site), no one showed a serious adverse reaction, all participants formed antibodies. Higher doses lead to more antibodies, but also lead to stronger adverse reactions.